ESGO/ESTRO/ESP 宫颈癌患者管理指南
欧洲妇科肿瘤学会(ESGO)、欧洲放射肿瘤学会(ESTRO)和欧洲病理学会(ESP)联合制定宫颈癌管理指南,由23名欧洲多学科专家基于系统检索的文献和专家共识制定,经159名国际评审人审阅。指南全面涵盖分期、管理和随访,包括保留生育功能治疗、各期别宫颈癌管理、妊娠期宫颈癌和复发疾病,并定义了放疗原则和病理评估原则。
要点
- 指南由ESGO/ESTRO/ESP联合制定,覆盖宫颈癌分期、管理和随访全程。
- 管理涵盖保留生育功能、早期至局部晚期、转移、妊娠期及复发宫颈癌。
- 指南定义了放疗原则和病理评估原则,基于最佳证据和专家共识。
核心结论
- ESGO/ESTRO/ESP联合制定循证指南以改善欧洲及全球宫颈癌女性诊疗质量。
研究设计与样本
- 由ESGO/ESTRO/ESP提名23名欧洲多学科专家组成制定组,基于系统检索文献和专家共识制定。
- 指南发布前由159名国际评审人(含患者代表)审阅。
主要发现
- 指南全面涵盖宫颈癌分期、管理和随访。
- 管理包括保留生育功能治疗、T1a、T1b1/T2a1、简单子宫切除术后发现的临床隐匿宫颈癌、早期和局部晚期宫颈癌、原发远处转移、妊娠期宫颈癌及复发疾病。
- 指南定义了放疗原则和病理评估原则。
临床怎么用
- 临床可参照该指南进行宫颈癌分期、管理决策和随访。
- 保留生育功能、各期别宫颈癌、妊娠期及复发疾病的管理可按指南推荐执行。
- 放疗实施和病理评估应遵循指南定义的原则。
局限性
- 缺乏明确科学证据时,推荐基于制定组的专业经验和共识。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite significant advances in the screening, detection, and treatment of preinvasive cervical lesions, invasive cervical cancer is the fifth most common cancer in European women. There are large disparities in Europe and worldwide in the incidence, management, and mortality of cervical cancer. OBJECTIVE: The European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly develop clinically relevant and evidence-based guidelines in order to improve the quality of care for women with cervical cancer across Europe and worldwide. METHODS: The ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of cervical cancer (23 experts across Europe). To ensure that the guidelines are evidence based, the current literature identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 159 international reviewers, selected through ESGO/ESTRO/ESP and including patient representatives. RESULTS: The guidelines cover comprehensively staging, management, and follow-up for patients with cervical cancer. Management includes fertility sparing treatment; stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy; early and locally advanced cervical cancer; primary distant metastatic disease; cervical cancer in pregnancy; and recurrent disease. Principles of radiotherapy and pathological evaluation are defined.
引用
- Cibula D, Pötter R, Planchamp F, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Radiother Oncol. 2018. PMID: 29728273. doi:10.1016/j.radonc.2018.03.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。